GlaxoSmithKline: Robust Pipeline Supports its 5.5% Dividend Yield

GlaxoSmithKline’s broad-based growth is thanks largely to its product innovation. Overall, GlaxoSmithKline spent $3.3 billion on research and development last year, and has a robust pipeline to show for it.